In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on POINT Biopharma Global (PNT – Research Report), with a price target of $18.00. The company’s shares closed yesterday at $5.72.
According to TipRanks, Walsh is an analyst with an average return of -29.6% and a 21.88% success rate. Walsh covers the Healthcare sector, focusing on stocks such as POINT Biopharma Global, Actinium Pharmaceuticals, and Plus Therapeutics.
Currently, the analyst consensus on POINT Biopharma Global is a Strong Buy with an average price target of $19.57, implying a 242.13% upside from current levels. In a report released today, Berenberg Bank also maintained a Buy rating on the stock with a $18.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $10.98 and a one-year low of $4.25. Currently, POINT Biopharma Global has an average volume of 848K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Therapeutics Acquisition Corp is a blank check company.
Read More on PNT:
